Systems > R&D Activities
OPTOGENERAPY – OPTOGENETIC PROTEIN THERAPY FOR MULTIPLE SCLEROSIS
ASE Optics Europe starts a new European project within the H2020 framework program: Optogenerapy. The project proposes a new drug delivery system to revolutionize Multiple Sclerosis treatment.
The aim is to develop and validate a new bio-electronic cell based implant device to be implanted subcutaneously providing controlled drug release during at least 6 months. The cell confinement within a chamber sealed by a porous membrane allows the device to be easily implanted or removed. At the same time, this membrane acts to prevent immune rejection and offers long-term safety in drug release while overcoming the adverse effects of current cellular therapies. Wireless powered optogenetics – light controlling the cellular response of genetically engineered cells – is used to control the production of IFN-ß (interferon beta).
FABIMED – FABRICATION AND FUNCTIONALIZATION OF BIOMEDICAL MICRODEVICES
The aim of FaBiMed (Fabrication and Functionalization of BioMedical Microdevices) proposal is to improve and develop new manufacturing techniques, based on micromoulding, specific for biomedical microdevices. The project will be to reducing the cost of mass production of diagnosis and therapeutic micro devices which have a common problematic: medium sized batches, customization needs, micron-scale geometrical features.
An innovative approach using the blue part of the spectrum for the OCT beam was taken so as to increase the depth of focus of the inspection beam to allow it to better reach the bottom of high aspect ratio features typical for the devices to be inspected.
ASE Optics Europe is the Leader of Work Package 4: Inspection and Quality Control. The main objective of WP4 is to provide fast and non-destructive means to control de processes and the quality of the devices which are developed and produced within the project using two main technologies: Optical Coherence Tomography and Laser Ultra Sound